PeptidesRx Review

Appears to have shut down
7.2

PeptidesRx is closed and is not taking new patients. It charged from $169 a month.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

PeptidesRx is no longer taking new patients. This program appears to have shut down, so we're not linking to it. Here are the top-rated GLP-1 providers we recommend instead.

Last published price before it closed: $169/mo. No longer offered.

See our top-rated GLP-1 providers →
Compare top-rated alternatives ↓

PeptidesRx sold compounded semaglutide and tirzepatide. In October 2026 every page of its site read “Temporarily Closed” and “under construction”. The record stays closed until the site reopens.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

Vetted alternatives to PeptidesRx

9.3/ 10
Verified partner

Embody

Best for: a flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies

★★★★★9.3/10

Editorial score · methodology

$79/mo
CompoundedSemaglutideTirzepatideGlutathioneNAD+
Get StartedRead full Embody review →
9.1/ 10
Verified partner

Collective

Best for: flat any-dose pricing, if you can absorb a $199 annual membership on top

★★★★★9.1/10

Editorial score · methodology

$59/mo+ membership
CompoundedSemaglutideTirzepatide
Get StartedRead full Collective review →
7.4/ 10
Verified partner

AgelessRx

Best for: microdosed compounded GLP-1s from a longevity clinic, or brand Wegovy at manufacturer pricing plus monitoring

★★★★☆7.4/10

Editorial score · methodology

$99/moprepaid
CompoundedSemaglutideTirzepatideGHK-CuGlutathione
Get StartedRead full AgelessRx review →
PeptidesRx
7.2 / 10
Our editorial rating

PeptidesRx at a glance

Status
Closed: not taking new patients
Type
GLP-1 telehealth provider
Medications
Semaglutide, Tirzepatide
Last published price
$169/mo
What it included
Consult
FDA status
No FDA warning letters found

How PeptidesRx scores

PeptidesRx has closed. These scores describe what it published when we last checked it, before it stopped taking patients.

Six columns, each one computed from something PeptidesRx published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where a seller keeps something back, such as its price or its pharmacy, the score reflects it. Every seller we review goes through the same six columns.

Value25%

6.2/10

$169/month is 15% below the $199 median for compounded semaglutide across the sellers we compare.

Effectiveness25%

10.0/10

Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).

User Experience15%

8.0/10

A price is shown before the questionnaire starts.

Trust & Safety15%

6.5/10

No pharmacy is named for its prescriptions. It shows a price before asking for health information.

Accessibility10%

5.0/10

No state list is available to check, so this is held at the midpoint rather than scored on reach.

Support10%

5.0/10

States too little about what the monthly cost covers to score the bundle. Held at the midpoint rather than assumed.

6weighted dimensions
734sellers compared
Everychecked against the seller's own site
Value 25%Effectiveness 25%User Experience 15%Trust & Safety 15%Accessibility 10%Support 10%

A seller that shows no price until after the medical intake loses points on User Experience and Trust & Safety, and its review says so. How we score →

What we checked on PeptidesRx

Last checked October 2026
  • Checked the listed price across 3 dose or plan tiers
  • Checked what the monthly price covers, and what it leaves out
  • Checked FDA warning letters for PeptidesRx

Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below.

Medications PeptidesRx listed

PeptidesRx listed compounded semaglutide and compounded tirzepatide. Each one has its own guide: how it works, the dosing schedule, the side effects that show up in practice, and what the trials measured.

Peptides PeptidesRx offers

PeptidesRx sells peptides beyond the GLP-1s. Tap one to read what the evidence says about it.

Prices it published before closing

Prices re-verified

0.25mgCompounded
$169/mo
semaglutide
1mgCompounded
$239/mo
semaglutide
2.5mgCompounded
$309/mo
tirzepatide

In its favor

  • Semaglutide cost $169 a month, 15% below the $199 median for compounded semaglutide across the sellers we compare
  • Tirzepatide cost $309 a month, close to the $269 median for compounded tirzepatide across the sellers we compare
  • Showed its price before the medical questionnaire, so you could compare it without handing over health information
  • The monthly price included clinician visits
  • We found no FDA warning letters issued to PeptidesRx

Against it

  • Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality

PeptidesRx is no longer taking new patients. What follows describes the program as it last ran, for anyone comparing it with a seller that is still open.

What PeptidesRx charged

PeptidesRx charged $169/month.

  • Compounded semaglutide (0.25 mg): $169/month
  • Compounded semaglutide (1 mg): $239/month
  • Compounded tirzepatide: $309/month

For compounded semaglutide, the median across the sellers we compare is $199/month, so PeptidesRx's $169 is genuinely below the middle, not just advertised that way.

MEDGm, at about $169/month, is the closest like-for-like alternative we review.

What PeptidesRx dispensed

PeptidesRx prescribed semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the two best-evidenced weight-loss molecules currently on the market. What arrives is compounded at a licensed pharmacy, not an approved pen. That is the reason it costs less, and the reason the finished preparation carries no FDA review behind it.

Safety and disclosure

PeptidesRx told buyers its price before the medical questionnaire. We found no FDA warning letters issued to PeptidesRx. How we weigh oversight, disclosure and price is set out in our scoring methodology.

Our read

PeptidesRx is no longer taking new patients, so the choice is among the sellers that are still open.

The Bottom Line

PeptidesRx is closed and is not taking new patients. It charged from $169 a month.

Score: 7.2/10Best for: compounded semaglutide at $169/monthFrom: $169/mo

Where PeptidesRx is the wrong choice

No seller suits every reader, and pretending otherwise is the easiest way to sell one. On these three counts, another seller does better.

  • If you need the FDA-approved pen rather than a compounded vial, consider WellMedRx.
  • If the standing monthly cost is what decides it, consider Collective (from $59/mo + membership).
  • If you want a human checking in, not just a prescription, consider Eden.

If none of these fits, our guide to alternatives to PeptidesRx sets more sellers in the same category beside PeptidesRx on price, states and what the price includes.

Frequently Asked Questions

PeptidesRx sold compounded semaglutide and tirzepatide. In October 2026 every page of its site read “Temporarily Closed” and “under construction”. The record stays closed until the site reopens. We rate it 7.2/10 overall.
PeptidesRx is no longer taking new patients: the program appears to have shut down, so there is nothing to sign up for. The alternatives listed on this page are still open.
Before it closed, PeptidesRx listed prices from $169 a month. The pricing table above shows every price it published.
PeptidesRx is no longer taking new patients in any state.
PeptidesRx listed compounded semaglutide and compounded tirzepatide.
PeptidesRx listed compounded GLP-1s only. A licensed compounding pharmacy prepares them: same active ingredient as the brand drug, lower cash price, and no FDA approval of the finished product.
PeptidesRx said the price covered the clinician visit.
You can't: PeptidesRx is no longer taking new patients. The alternatives listed on this page are still open.
PeptidesRx is no longer taking new patients, so there is nothing to buy. We found no FDA warning letters issued to PeptidesRx.
Other sellers we cover include MEDGm, MyDrHank, and HealthRX. Which one fits depends on the medication, the monthly price you can sustain and whether it ships to your state, so compare those three facts before you switch.

Glossary

The words sellers use, defined. Tap any term.

Sources

Cited across this PeptidesRx review: primary regulatory filings, and peer-reviewed studies.

Sources & methodology — as of October 2026
  1. 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
  2. 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  3. 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  4. 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
  5. 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
  6. 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
  7. 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  8. 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
  9. 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
  10. 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  11. 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
  12. 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Aronne LJ et al.)— New England Journal of Medicine.PMID: 40353578.